• 1. An alternative biorefinery approach to address microalgal seasonality: blending with spent coffee grounds
  Andre Prates Pereira,Tao Dong,Eric P. Knoshaug,Nick Nagle,Ryan Spiller,Bonnie Panczak,Christopher J. Chuck,Philip T. Pienkos Sustainable Energy Fuels, 2020,4, 3400-3408
• 2. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 3. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996
• 4. An atomically efficient, highly stable and redox active Ce0.5Tb0.5Ox (3% mol.)/MgO catalyst for total oxidation of methane?
  Juan J. Sánchez,Miguel López-Haro,Juan C. Hernández-Garrido,Ginesa Blanco,Miguel A. Cauqui,José M. Rodríguez-Izquierdo,José A. Pérez-Omil,José J. Calvino,María P. Yeste J. Mater. Chem. A, 2019,7, 8993-9003
• 5. An insight into the hybridization mechanism of hairpin DNA physically immobilized on chemically modified graphenes
  Adeline Huiling Loo,Alessandra Bonanni,Martin Pumera Analyst, 2013,138, 467-471

Introduction to 5-Bromo-1-(3-chlorophenyl)-1H-pyrazole-4-carboxylic acid (CAS No. 959576-61-5)

5-Bromo-1-(3-chlorophenyl)-1H-pyrazole-4-carboxylic acid is a specialized organic compound that has garnered significant attention in the field of pharmaceutical and medicinal chemistry due to its unique structural properties and potential biological activities. With the CAS number 959576-61-5, this compound represents a promising scaffold for the development of novel therapeutic agents. Its molecular structure, featuring both bromo and chloro substituents on a pyrazole core, makes it an intriguing candidate for further exploration in drug discovery.

The pyrazole moiety is a heterocyclic aromatic ring system that is widely recognized for its presence in numerous bioactive molecules. Pyrazoles exhibit a broad spectrum of biological activities, including anti-inflammatory, antimicrobial, antiviral, and anticancer properties. The introduction of halogen atoms such as bromine and chlorine into the pyrazole framework can modulate its pharmacokinetic and pharmacodynamic profiles, enhancing its interaction with biological targets. This modification has been strategically employed to develop more potent and selective drug candidates.

In recent years, there has been a surge in research focused on designing small-molecule inhibitors targeting various enzymes and receptors involved in disease pathways. 5-Bromo-1-(3-chlorophenyl)-1H-pyrazole-4-carboxylic acid has been identified as a potential lead compound in this context. Its ability to interact with specific binding sites on enzymes or receptors makes it a valuable tool for structure-activity relationship (SAR) studies. These studies aim to optimize the compound's potency, selectivity, and pharmacological properties.

One of the most compelling aspects of this compound is its versatility in medicinal chemistry applications. The presence of both bromo and chloro substituents provides multiple sites for chemical modification, allowing researchers to fine-tune its biological activity. For instance, the bromine atom can be readily functionalized via cross-coupling reactions, while the carboxylic acid group offers opportunities for amide bond formation, leading to the synthesis of peptidomimetics or other bioconjugates.

Recent advancements in computational chemistry have further accelerated the discovery process for compounds like 5-Bromo-1-(3-chlorophenyl)-1H-pyrazole-4-carboxylic acid. Molecular docking simulations have been employed to predict the binding affinity of this compound to various biological targets. These simulations have revealed promising interactions with enzymes such as kinases and phosphodiesterases, which are implicated in cancer and inflammatory diseases. The results from these computational studies have guided experimental efforts toward optimizing the compound's therapeutic potential.

The synthesis of 5-Bromo-1-(3-chlorophenyl)-1H-pyrazole-4-carboxylic acid involves multi-step organic reactions that require careful optimization to ensure high yield and purity. The bromination and chlorination steps are critical and must be carefully controlled to avoid unwanted side products. Advances in synthetic methodologies have enabled more efficient and scalable production of this compound, making it more accessible for preclinical and clinical investigations.

In the realm of drug discovery, 5-Bromo-1-(3-chlorophenyl)-1H-pyrazole-4-carboxylic acid has been explored as a potential therapeutic agent for several diseases. Preliminary studies have suggested its efficacy in inhibiting pathways associated with neurodegenerative disorders such as Alzheimer's disease. The pyrazole core interacts with amyloid-beta plaques, which are hallmark pathological features of this condition. Additionally, the compound has shown promise in preclinical models of cancer, where it demonstrates inhibitory effects on tumor growth by targeting specific signaling pathways.

The pharmacokinetic profile of 5-Bromo-1-(3-chlorophenyl)-1H-pyrazole-4-carboxylic acid is another area of interest. Researchers are investigating its absorption, distribution, metabolism, excretion (ADME) properties to ensure its suitability for therapeutic use. Understanding these parameters is crucial for determining appropriate dosing regimens and predicting potential drug-drug interactions. In vitro studies have provided valuable insights into how this compound behaves within biological systems, guiding efforts to improve its bioavailability and therapeutic efficacy.

The role of 5-Bromo-1-(3-chlorophenyl)-1H-pyrazole-4-carboxylic acid in combinatorial therapy is also being explored. By pairing this compound with other drugs that target different disease mechanisms, researchers aim to achieve synergistic effects that could enhance treatment outcomes. Combinatorial approaches have shown significant promise in overcoming drug resistance and improving patient responses in various conditions.

Future directions in the research of 5-Bromo-1-(3-chlorophenyl)-1H-pyrazole-4-carboxylic acid include further exploration of its mechanism of action and clinical translation into human trials. Investigating how this compound interacts with cellular components at a molecular level will provide deeper insights into its therapeutic effects. Additionally, conducting Phase I/II clinical trials will help assess its safety profile and efficacy in patients with relevant diseases.

The development of novel pharmaceuticals relies heavily on innovative compounds like 5-Bromo-1-(3-chlorophenyl)-1H-pyrazole-4-carboxylic acid. Its unique structural features make it a valuable asset in the medicinal chemist's toolkit, offering opportunities for designing next-generation therapeutics with improved efficacy and safety profiles.

• 110821-39-1(Ethyl 5-bromo-1-(3-chlorophenyl)-1H-pyrazole-4-carboxylate)
• 98534-71-5(Ethyl 5-bromo-1-phenyl-1H-pyrazole-4-carboxylate)
• 1245258-73-4(Ethyl 5-bromo-1-(4-bromophenyl)-1H-pyrazole-4-carboxylate)
• 959578-19-9(Ethyl 5-Bromo-1-(4-methylphenyl)-1H-pyrazole-4-carboxylate)
• 110821-40-4(Ethyl 5-bromo-1-(4-chlorophenyl)-1H-pyrazole-4-carboxylate)
• 1399654-57-9(5-Bromo-1-(4-chlorophenyl)-1H-pyrazole-4-carboxylic acid)
• 1245259-89-5(Ethyl 5-bromo-1-(2-chlorophenyl)-1H-pyrazole-4-carboxylate)
• 1269291-97-5(5-Bromo-1-(3-chlorophenyl)-1H-pyrazole-4-carbonitrile)
• 54367-65-6(5-Bromo-1-Phenyl-1h-Pyrazole-4-Carboxylic Acid)
• 1245272-41-6(5-Bromo-1-m-tolyl-1H-pyrazole-4-carboxylic acid ethyl ester)